Summary
Updated Aug 30, 2026
Oren Gilad is President/CEO, Director of Aprea Therapeutics, Inc. (APRE). 5 SEC Form 4 filings on record going back to 2024, most recently on 16 March 2026. Most recent open-market trade: bought $25K of APRE on 2 February 2026. Lifetime open-market purchases: $31K. Historical track record: 4/5 stars across 5 tracked purchases.
Recent Transactions
6Every recent SEC Form 4 transaction Oren Gilad has reported, most recent first.
Track Record
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realized performance after each tracked open-market purchase.
| Metric | Value |
|---|---|
| InsiderAlpha rating | ★★★★☆ (4/5) |
| Total purchases tracked | 5 |
| Purchases with forward-return data | 5 |
| 30-day win rate | 80% |
| 90-day win rate | 100% |
| Avg 5-day return | +24.59% |
| Avg 30-day return | +12.47% |
| Avg 90-day return | +21.04% |
| Best 30-day return | +38.58% |
Trading Pattern
InsiderAlpha's records for Oren Gilad go back to 2024: 5 primary Form 4 filings, an average of 1.7 per year. The typical open-market purchase is $5K (6 buys totaling $31K). The largest single buy on record is $25K of APRE in 2026. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Oren Gilad files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Richard Peters - $100K of APRE open-market activity in the last 12 months
- John P. Hamill - $30K of APRE open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Oren Gilad?
Oren Gilad is a corporate insider, tracked as President/CEO, Director of Aprea Therapeutics, Inc. (APRE). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Oren Gilad last file a Form 4?
The most recent primary Form 4 on record is dated 16 March 2026, one of 5 filings going back to 2024.
Has Oren Gilad been buying or selling stock?
Recorded transactions: 6 open-market purchases ($31K) and 0 open-market sales across all tracked filings.
How accurate is Oren Gilad's historical track record?
Across 5 tracked purchases, Oren Gilad averaged +12.5% avg 30-day return with a 80% 30-day win rate. InsiderAlpha rates the track record at 4/5 stars.
Where can I see all of Oren Gilad's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Oren Gilad and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial